Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maguire, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maguire, G.
American Journal of Health-System Pharmacy, Vol 59, Issue suppl_5, S4-S11
Copyright © 2002 by American Society of Health-System Pharmacists


Articles

Comprehensive understanding of schizophrenia and its treatment

GA Maguire


An overview of schizophrenia is presented, including diagnostic criteria, etiology, neurologic findings, pharmacotherapy options, quality-of-life issues, and the financial impact of the disease. Schizophrenia is a chronic disease characterized by positive symptoms, negative symptoms, mood symptoms, and cognitive deficits. Often comorbid substance abuse is present. Schizophrenia accounts for 20% of all hospital bed-days and over 50% of all psychiatric beds in the United States. There is a strong genetic component to schizophrenia, and other possible contributing factors are explored. The diagnostic workup should include a detailed longitudinal history, mental status exam, physical and neurologic exams, and laboratory tests. A magnetic resonance imaging scan can rule out structural causes of psychosis and should be considered at the time of diagnosis. Treatment is based on a biopsychosocial model including pharmacotherapy in combination with individual, group, and family therapies. Rather than classifying antipsychotics as typical or atypical, a new classification scheme has been proposed based on risk of causing extrapyramidal symptoms and tardive dyskinesia (TD), effect on prolactin level, and efficacy profile: first-generation or traditional agents (e.g., chlorpromazine and haloperidol); second-generation agents (e.g., risperidone and ziprasidone); and third-generation agents (e.g., clozapine, olanzapine, and quetiapine). The binding affinities of antipsychotics in the brain help explain the mechanisms by which different antipsychotics alleviate specific symptoms of schizophrenia, as well as cause specific adverse effects. Improved cognition, fewer depressive and mood symptoms, and decreased risk of TD associated with third-generation antipsychotics have improved the quality of life for patients with schizophrenia.
 



This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
W.-J. Gao
Acute Clozapine Suppresses Synchronized Pyramidal Synaptic Network Activity by Increasing Inhibition in the Ferret Prefrontal Cortex
J Neurophysiol, February 1, 2007; 97(2): 1196 - 1208.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society of Health-System Pharmacists.